LOG IN
SIGN UP
MARKET
AGEN
AGEN
Agenus
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.960
+0.020
+1.03%
After Hours: 1.910 -0.05 -2.55% 19:10 07/01 EDT
OPEN
1.940
PREV CLOSE
1.940
HIGH
1.965
LOW
1.850
VOLUME
4.88M
TURNOVER
0
52 WEEK HIGH
6.79
52 WEEK LOW
1.250
MARKET CAP
554.40M
P/E (TTM)
-21.0300
1D
5D
1M
3M
1Y
5Y
Agenus to Participate at William Blair’s Biotech Focus Conference
LEXINGTON, Mass., June 30, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced that Dr. Steven O’Day, Chie...
GlobeNewswire · 2d ago
U.S. Stocks Turn Negative; 2U Shares Spike Higher
U.S. stocks pared gains midway through trading, with all the three major indices turning lower on Wednesday.
Benzinga · 3d ago
Agenus adds 24% on early-stage data for colorectal cancer drugs
The shares of Agenus (NASDAQ:AGEN) surged ~24% i...
Seekingalpha · 3d ago
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
Agenus Inc (NASDAQ: AGEN) has announced expanded data from the Phase 1b study of botensilimab and balstilimab in patients with microsatellite stable colorectal cancer. The data demonstrate that the combination offers strong durability and superior efficacy...
Benzinga · 3d ago
BRIEF-Agenus Shows Unprecedented Activity For Botensilimab/Balstilimab Combination In Microsatellite Stable Colorectal Cancer At Esmo World Gi Congress
BRIEF-Agenus Shows Unprecedented Activity For Botensilimab/Balstilimab Combination In Microsatellite Stable Colorectal Cancer At Esmo World Gi Congress
Reuters · 3d ago
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI Congress
LEXINGTON, Mass., June 21, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will host a hyb...
GlobeNewswire · 06/21 12:30
MFGP, SRNE and OPEN among pre market losers
AC Immune ACIU -32% as crenezumab fails in Alzheimer's study. Cango (CANG) -30%. Absci (ABSI) -14%. Hillstream BioPharma (HILS) -11%. Cepton (CPTN) -7%. Enservco Corporation (ENSV) -10%. Arcellx ACLX -10% on upsizing of follow-on
Seekingalpha · 06/16 12:35
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows.
Benzinga · 06/13 16:18
No Data
Learn about the latest financial forecast of AGEN. Analyze the recent business situations of Agenus through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 4 analysts
Strong Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average AGEN stock price target is 9.67 with a high estimate of 14.00 and a low estimate of 7.00.
Current 1.960
EPS
Actual
Estimate
-0.120.140.390.65
Institutional Holdings
Institutions: 217
Institutional Holdings: 138.09M
% Owned: 51.09%
Shares Outstanding: 282.86M
TypeInstitutionsShares
Increased
55
7.04M
New
25
16.26M
Decreased
50
16.18M
Sold Out
29
5.35M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Garo Armen
Vice President - Finance
Christine Klaskin
Other
Steven O'Day
Lead Director/Independent Director
Timothy Wright
Independent Director
Brian Corvese
Independent Director
Susan Hirsch
Independent Director
Allison Jeynes-Ellis
Independent Director
Wadih Jordan
Independent Director
Ulf Wiinberg
No Data
No Data
About AGEN
Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.
Webull offers kinds of Agenus Inc stock information, including NASDAQ:AGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AGEN stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading AGEN stock methods without spending real money on the virtual paper trading platform.